Search Results
You are looking at 1 - 2 of 2 items for
- Author: Jie Lu x
- Refine by access: All content x
Search for other papers by Jinke Wang in
Google Scholar
PubMed
Search for other papers by Jie Lu in
Google Scholar
PubMed
Search for other papers by Guangming Gu in
Google Scholar
PubMed
Search for other papers by Yingxun Liu in
Google Scholar
PubMed
The DNA-binding specificity of transcription factors (TFs) has broad impacts on cell physiology, cell development and in evolution. However, the DNA-binding specificity of most known TFs still remains unknown. The specificity of a TF protein is determined by its relative affinity to all possible binding sites. In recent years, the development of several in vitro techniques permits high-throughput determination of relative binding affinity of a TF to all possible k bp-long DNA sequences, thus greatly promoting the characterization of DNA-binding specificity of many known TFs. All DNA sequences that can be bound by a TF with various binding affinities form their DNA-binding profile (DBP). The DBP is important to generate an accurate DNA-binding model, identify all DNA-binding sites and target genes of TFs in the whole genome, and build transcription regulatory network. This study reviewed these techniques, especially two master techniques: double-stranded DNA microarray and systematic evolution of ligands by exponential enrichment in combination with parallel DNA sequencing techniques (SELEX-seq).
Search for other papers by Shou-Si Lu in
Google Scholar
PubMed
Search for other papers by Yun-Li Yu in
Google Scholar
PubMed
Search for other papers by Hao-Jie Zhu in
Google Scholar
PubMed
Search for other papers by Xiao-Dong Liu in
Google Scholar
PubMed
Search for other papers by Li Liu in
Google Scholar
PubMed
Search for other papers by Yao-Wu Liu in
Google Scholar
PubMed
Search for other papers by Ping Wang in
Google Scholar
PubMed
Search for other papers by Lin Xie in
Google Scholar
PubMed
Search for other papers by Guang-Ji Wang in
Google Scholar
PubMed
Berberine (BBR), a hypoglycemic agent, has shown beneficial metabolic effects for anti-diabetes, but its precise mechanism was unclear. Glucagon-like peptide-1 (GLP-1) is considered to be an important incretin that can decrease hyperglycemia in the gastrointestinal tract after meals. The aim of this study was to investigate whether BBR exerts its anti-diabetic effects via modulating GCG secretion. Diabetes-like rats induced by streptozotocin received BBR (120 mg/kg per day, i.g) for 5 weeks. Two hours following the last dose, the rats were anaesthetized and received 2.5 g/kg glucose by gavage. At 15-minute and 30-minute after glucose load, blood samples, pancreas, and intestines were obtained to measure insulin and GCG using ELISA kit. The number of L cells in the ileum and β-cells in the pancreas were identified using immunohistology. The expression of proglucagon mRNA in the ileum was measured by RT-PCR. The results indicated that BBR treatment significantly increased GCG levels in plasma and intestine (P<0.05) accompanied with the increase of proglucagon mRNA expression and the number of L-cell compared with the controls (P<0.05). Furthermore, BBR increased insulin levels in plasma and pancreas as well as β-cell number in pancreas. The data support the hypothesis that the anti-diabetic effects of BBR may partly result from enhancing GCG secretion.
